Prognostic factors of early recurrence after complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Table 3 Analysis of the risk of recurrence within 1 year using a simple logistic regression model

Parameter	Crude OR (95%CI)	P value
Age in yr
≥ 55	0.546 (0.222, 1.343)	0.188
< 55	1.000
Sex
Female	0.662 (0.261, 1.681)	0.386
Male	1.000
Previous systemic therapy
Any	1.603 (0.574, 4.482)	0.368
Never	1.000
Clinical presentation
Primary	1.210 (0.500, 2.931)	0.673
Recurrence	1.000
Cancer type
Ovary	0.646 (0.239, 1.746)	0.389
GI	1.000
CC score
0	0.141 (0.037, 0.541)	0.004a
1	1.000
PCI score
1-7	0.444 (0.180, 1.095)	0.078
8-39	1.000
HIPEC regimen
Cisplatin	1.778 (0.657, 4.809)	0.257
Non-cisplatin	1.000
HIPEC duration in min
≤ 60	1.565 (0.632, 3.879)	0.333
90	1.000
Extraperitoneal oligometastasis
Any	1.071 (0.401, 2.830)	0.890
None	1.000
Surgical method
Laparoscopy	0.858 (0.239, 3.077)	0.814
Laparotomy	1.000
Histology grade
Grade 1/2	0.656 (0.270, 1.597)	0.353
Grade 3	1.000
Pre-HIPEC chemotherapy1
Yes	2.259 (0.922, 5.532)	0.075
No	1.000
Post-HIPEC chemotherapy2
Yes	1.500 (0.389, 5.781)	0.556
No	1.000
CRS time in h
≤ 6	0.361 (0.146, 0.892)	0.027a
> 6	1.000
Bowel resection
Yes	2.143 (0.858, 5.351)	0.103
No	1.000

^aP < 0.05.

¹Within 6 mo before hyperthermic intraperitoneal chemotherapy (HIPEC);

²Within 6 mo after HIPEC.

CC: Completeness of cytoreduction; CI: Confidence interval; CRS: Cytoreductive surgery; GI: gastrointestinal cancers, including gastric, colorectal and appendiceal cancers; HIPEC: Hyperthermic intraperitoneal chemotherapy; OR: Odds ratio; PCI: Peritoneal cancer index.